Breaking News Instant updates and real-time market news.

ABBV

AbbVie

, ACAD

ACADIA

$30.71

-1.1 (-3.46%)

10:25
10/04/16
10/04
10:25
10/04/16
10:25

Piper Jaffray biopharma analyst holds an analyst/industry conference call

Biopharmaceuticals Analyst Schimmer, along with Professor Standaert, Chairperson of Neurology at the University of Alabama, discuss the current treatment paradigm for Parkinson's disease including the role of L-Dopa therapy and deep brain stimulation (DBS), the unmet need and potential for new therapies, including VYGR's gene therapy approach, anti-alpha-synuclein therapy, long-acting and formulations of L-Dopa on an Analyst/Industry conference call to be held on October 4 at 11 am.

ABBV

AbbVie

ACAD

ACADIA

$30.71

-1.1 (-3.46%)

ACOR

Acorda Therapeutics

$20.83

-0.05 (-0.24%)

BIIB

Biogen

$311.59

-1.44 (-0.46%)

CYNA

Cynapsus Therapeutics

$40.21

-0.02 (-0.05%)

IPXL

Impax

$23.81

0.11 (0.46%)

MDT

Medtronic

$86.45

0.06 (0.07%)

NDRM

NeuroDerm

$18.43

-0.06 (-0.32%)

PRTA

Prothena

$59.76

-0.21 (-0.35%)

VYGR

Voyager Therapeutics

$11.94

-0.07 (-0.58%)

  • 04

    Oct

  • 06

    Oct

  • 26

    Oct

  • 06

    Nov

  • 10

    Nov

ABBV AbbVie

09/01/16
RAJA
09/01/16
INITIATION
Target $82
RAJA
Outperform
AbbVie initiated with an Outperform at Raymond James
Target $82.
09/02/16
09/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AbbVie (ABBV) initiated with an Outperform at Raymond James. 2. Spark Therapeutics (ONCE) initiated with a Buy at Stifel. 3. Cornerstone OnDemand (CSOD) initiated with an Overweight at Piper Jaffray. 4. UR-Energy (URG) initiated with an Outperform at FBR Capital. 5. Energy Transfer Equity (ETE) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/08/16
JPMS
09/08/16
DOWNGRADE
Target $73
JPMS
Neutral
AbbVie downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Chris Schott downgraded AbbVie (ABBV) to Neutral citing the stock's 10% rally year-to-date and limited near-term catalysts. AbbVie's profile is now better reflected at current valuation levels, Schott tells investors in a research note. He lowered his price target for the shares to $73 from $75. The analyst coupled the downgrade with an upgrade this morning of Eli Lilly (LLY) to Overweight.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
ACAD ACADIA
$30.71

-1.1 (-3.46%)

10/04/16
LEER
10/04/16
INITIATION
Target $34
LEER
Market Perform
ACADIA reinstated with a Market Perform at Leerink
Leerink analyst Paul Matteis resumed coverage of ACADIA with a Market Perform rating and $34 price target.
08/05/16
AGIS
08/05/16
DOWNGRADE
Target $41
AGIS
Hold
ACADIA downgraded to Hold from Buy at Aegis
Aegis analyst Robert Leboyer downgraded ACADIA Pharmaceuticals to Hold with a $41 price target saying the stock at current levels is fairly valued.
07/08/16
PIPR
07/08/16
NO CHANGE
Target $44
PIPR
Overweight
Piper reiterates Overweight on ACADIA following physician survey
Piper Jaffray analyst Charles Duncan says his firm's recent survey of U.S. neurologists and psychiatrists who treat Parkinson's disease patients provides further support for his "non-consensus" revenue build for ACADIA's Nuplazid in Parkinson's disease psychosis. Sentiment for the drug is positive, and doctors see value in treating PDP, Duncan tells investors in a research note. He reiterates an Overweight rating on ACADIA with a $44 price target.
06/24/16
06/24/16
NO CHANGE

Needham sees Brexit making EU drug reviews 'less efficient, more expensive'
Needham analyst including Alan Carr, Chad Messer, Danielle Brill and Esther Pang noted that if Article 50 is invoked following the Brexit vote, the European Medicines Agency will need to move out of its current base in London and the U.K. will need to create its own separate regulatory organization for drugs, concluding that Brexit will lead to a "less efficient, more expensive, and potentially lengthier regulatory process" for drug approval in the EU and the U.K. Among the companies that are currently in discussions with the EMA or have drugs under MAA review, Needham lists ACADIA (ACAD) Celator (CPXX), Cempra (CEMP), Gilead (GILD) Intercept (ICPT), Seattle Genetics (SGEN), Valeant (VRX) and Progenics (PGNX).
ACOR Acorda Therapeutics
$20.83

-0.05 (-0.24%)

10/04/16
LEER
10/04/16
INITIATION
Target $25
LEER
Market Perform
Acorda Therapeutics reinstated with a Market Perform at Leerink
Leerink analyst Paul Matteis resumed coverage of Acorda Therapeutics with a Market Perform rating and $25 price target.
03/30/16
03/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Intercept (ICPT) initiated with an Outperform and a Neutral at Credit Suisse and Goldman, respectively. Goldman Sachs analyst Salveen Richter said investor expectations into the April 7 FDA panel for obeticholic acid in primary biliary cholangitis appear high. 2. Acorda Therapeutics (ACOR) initiated with a Sell at Goldman by analyst Salveen Richter, who said Acorda's lead product Ampyra is close to fully realizing its commercial opportunity and that intellectual property threats will present an overhang on the shares. 3. SAGE Therapeutics (SAGE) initiated with a Buy at Goldman due to the belief that the company is a key player in acute central nervous system disorders. 4. Rio Tinto (RIO) initiated with a Buy at Argus. 5. Square (SQ) initiated with a Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/30/16
GSCO
03/30/16
DOWNGRADE
Target $10
GSCO
Neutral
Dimension Therapeutics downgraded to Neutral from Buy at Goldman
Goldman Sachs analyst Salveen Richter downgraded Dimension Therapeutics (DMTX) to Neutral saying other names in the sector offer better near-term opportunities. The analyst views Dimension as well-positioned in the gene therapy space, however. He lowered his price target for the shares to $10 from $12. Richter this morning also initiated SAGE Therapeutics (SAGE) with a Buy rating and Acorda Therapeutics (ACOR) with a Sell rating.
03/30/16
GSCO
03/30/16
INITIATION
Target $23
GSCO
Sell
Acorda Therapeutics initiated with a Sell at Goldman
Goldman Sachs analyst Salveen Richter started Acorda Therapeutics with a Sell rating and $23 price target. The analyst believes Acorda's lead product Ampyra is close to fully realizing its commercial opportunity and that intellectual property threats will present an overhang on the shares.
BIIB Biogen
$311.59

-1.44 (-0.46%)

09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.
10/03/16
BMOC
10/03/16
NO CHANGE
Target $304
BMOC
Biogen potential trading opportunity into year-end, says BMO Capital
BMO Capital hosted a call with an expert on Alzheimers that may present a trading opportunity in Biogen (BIIB) shares as we approach sola Phase 3 and aducanumab titration data expected at year end. The expert said evidence supports the amyloid hypothesis of AD outweighs the evidence that undercuts it, but suggested that patient selection and trial design/execution key to demonstrating benefit to support regulatory approval. He estimated that Lilly's (LLY) EXPEDITION-3 trial has a ~60% probability of success, with Biogen's aducanumab greater than70% as long as rates of ARIA-E can be reduced with titration. Analyst Ian Somaiya believes positive Phase III Sola data could provide a positive read through to aducanumab and results in Biogen shares trading up 20-25%. If Sola misses, aducanumab's ability to clear beta amyloid oligomers & plaques and in our opinion a better trial design could limit downside in shares to approximately 10%. Somaiya rates Biogen a Market Perform with a $304 price target.
10/04/16
RBCM
10/04/16
NO CHANGE
Target $375
RBCM
Outperform
Biogen could rise $20 or more per share on SMA success, says RBC Capital
RBC Capital analyst Michael Yee expects the first presentation of data from Biogen's (BIIB) Phase III ENDEAR trial studying nusinersen, an investigational treatment for spinal muscular atrophy, or SMA, this week, potentially during the late breaker session at the WMS Congress on October 8. Biogen and partner Ionis Pharmaceuticals (IONS) already announced in August that the study in Type I infants hit the interim analysis and stopped early for positive data. The much larger opportunity in older children has data expected to read out in Spring 2017, noted Yee, who thinks Biogen can have upside from $10 to over $20 per share based on its SMA opportunity. Yee keeps an Outperform rating and $375 price target on Biogen shares.
CYNA Cynapsus Therapeutics
$40.21

-0.02 (-0.05%)

07/19/16
JANY
07/19/16
NO CHANGE
Target $24
JANY
Buy
Cynapsus Phase 3 DTP results bode well for study, says Janney Capital
Janney Capital analyst Ken Trbovich believes the open-label dose titration phase, or DTP, results reported by Cynapsus Therapeutics support his expectation that the Phase 3 trial will likely result in a clinically and statistically significant difference from placebo during the randomized portion of the study. The analyst keeps a Buy rating and $24 fair value estimate on Cynapsus shares.
07/20/16
BMOC
07/20/16
NO CHANGE
BMOC
Cynapsus Therapeutics price target raised to $25 from $21 at BMO Capital
BMO Capital increased its price target on Cynapsus citing its belief that the company's APL drug will be approved in Europe. The firm keeps an Outperform rating on the shares.
08/16/16
BMOC
08/16/16
NO CHANGE
BMOC
Cynapsus Therapeutics price target raised to $30 from $25 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Cynapsus after the Data and Safety Monitoring Board, or DSMB, said that patients participating in a trial of the company's APL at-home titration product could use it at home. The analyst thinks that at-home titration appeals to doctors, and he says that the DSMB's recommendation highlights the superior safety and tolerability of the product versus injectable Apokyn. The analyst keeps an Outperform rating on Cynapsus.
09/01/16
JANY
09/01/16
DOWNGRADE
Target $40.5
JANY
Neutral
Cynapsus Therapeutics downgraded to Neutral from Buy at Janney Capital
Janney Capital analyst Ken Trbovich downgraded Cynapsus Therapeutics to Neutral citing the company's takeover by Sunovion Pharmaceuticals. The analyst has a $40.50 price target for the shares.
IPXL Impax
$23.81

0.11 (0.46%)

06/29/16
06/29/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on the today's top five analyst initiations with this list compiled by The Fly: 1. Valeant (VRX) initiated with a Market Perform at BMO Capital by analyst Gary Nachman, who set a $26 price target on the stock. The analyst also initiated Mallinckrodt (MNK), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Flexion (FLXN) and Neos Therapeutics (NEOS) with Outperform ratings and Endo (ENDP), Impax (IPXL) and Amphastar (AMPH) with Market Perform ratings. 2. Regeneron (REGN) initiated with an Outperform rating and $400 target at Bernstein. The firm expects the sales of the company's Praluent drug to accelerate, and it believes that the shares have reached an attractive entry point following their steep decline since 2015. Bernstein also initiated Biogen (BIIB) with an Outperform rating and $282 target. 3. Newfield Exploration (NFX) initiated with a Buy at Canaccord by analyst Stephen Berman, citing its leading position in the Anadarko Basin SCOOP and STACK plays of Oklahoma, solid balance sheet, and cost efficiencies. Canaccord has a $48 price target on Newfield Exploration shares. 4. Fleetmatics (FLTX) initiated with an Overweight at Morgan Stanley by analyst James Faucette, who put a $52 price target on the stock. The analyst said improved commercial vehicle utilization is an underappreciated market opportunity and believes the company is well positioned to expand its value proposition and drive market adoption and up-sell subscriptions. Fleetmatics was also initiated with an Outperform rating and $52 target at Baird. 5. Pure Storage (PSTG) initiated with a Neutral at Baird as they sit on the sidelines waiting for clarity on the company's market share trajectory. Baird has a $12 price target on Pure Storage shares. Pure Storage was also initiated with an Outperform rating and $15 price target at Macquarie by analyst Rajesh Ghai. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/10/16
LEER
08/10/16
NO CHANGE
Target $24
LEER
Market Perform
Impax price target lowered to $24 from $33 at Leerink
After the company reported a "disappointing" top and bottom-line miss, Leerink analyst Jason Gerberry lowered his price target for Impax to $24 from $33 on the company's limited revenue upside and U.S. generics outlook. The analyst reiterates a Market Perform rating on the shares.
08/15/16
NORL
08/15/16
UPGRADE
NORL
Outperform
Impax upgraded to Outperform from Market Perform at Northland
09/27/16
GSCO
09/27/16
UPGRADE
Target $26
GSCO
Neutral
Impax upgraded to Neutral from Sell at Goldman
Goldman analyst Stephan Stewart upgraded Impax to Neutral citing balanced risk/reward and limited pricing risk. Stewart raised Impax's price target to $26 from $25.
MDT Medtronic
$86.45

0.06 (0.07%)

08/25/16
FBCO
08/25/16
NO CHANGE
Target $92
FBCO
Outperform
Medtronic price target raised to $92 from $85 at Credit Suisse
Credit Suisse analyst Matthew Keeler raised long-term estimates for Medtronic and increased its price target to $92 to reflect the company's restated revenue reporting lines and raised its out-yer Diabetes and margin estimates. Keeler continues to see upside to shares given Medtronic's solid free cash flow, strong pipeline, and above-market topline growth. The analyst has an Outperform rating on Medtronic shares.
08/26/16
PIPR
08/26/16
NO CHANGE
PIPR
Medtronic guidance conservative, says Piper Jaffray
After Medtronic reported higher than expected Q1 EPS and in-line revenue, Piper Jaffray analyst Brooks West says the quarter was "just fine." He says that the company's failure to raise its revenue guidance to reflect recent acquisitions was conservative and "de-risks" its now "beatable" guidance. West expects new products to bolster the company's revenue, and he predicts that it will continue to gain share in CRM. He keeps a $104 price target and Overweight rating on the stock.
09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
NDRM NeuroDerm
$18.43

-0.06 (-0.32%)

05/27/16
ROTH
05/27/16
NO CHANGE
Target $27.5
ROTH
Buy
NeuroDerm technology still underappreciated, says Roth Capital
Roth Capital analyst Scott Henry believes NeuroDerm could have a more "safe and efficacious" treatment for moderate to severe Parkinson's disease based on the potential for more consistent dosing of levodopa. The company's technology is still "underappreciated" by investors at this point in time, Henry notes. He reiterates a Buy rating and $27.50 price target on the shares.
11/11/15
11/11/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Albemarle (ALB) initiated with a Neutral at UBS... Ares Management (ARES) reinstated with an Overweight at JPMorgan... Cablevision (CVC) initiated with a Neutral at SunTrust... Canadian Solar (CSIQ) initiated with an Overweight at Morgan Stanley... Carriage Services (CSV) initiated with an Outperform at Oppenheimer... Charter (CHTR) initiated with a Buy at SunTrust... Cognex (CGNX) initiated with a Market Perform at FBR Capital... Comcast (CMCSA) initiated with a Neutral at SunTrust... CubeSmart (CUBE) initiated with a Buy at BB&T... Extra Space Storage (EXR) initiated with an Underweight at BB&T... FARO Technologies (FARO) initiated with a Market Perform at FBR Capital... IPG Photonics (IPGP) initiated with an Outperform at FBR Capital... NeuroDerm (NDRM) initiated with an Outperform at Raymond James... Perceptron (PRCP) initiated with an Outperform at FBR Capital... Proteon Therapeutics (PRTO) initiated with an Outperform at Raymond James... Public Storage (PSA) initiated with an Underweight at BB&T... Pure Storage (PSTG) initiated with a Neutral at Sterne Agee CRT... Service Corp. (SCI) initiated with an Outperform at Oppenheimer... Sovran Self Storage (SSS) initiated with a Buy at BB&T... Time Warner Cable (TWC) initiated with a Neutral at SunTrust.
11/10/15
RAJA
11/10/15
INITIATION
Target $28
RAJA
Outperform
NeuroDerm initiated with an Outperform at Raymond James
Target $28.
PRTA Prothena
$59.76

-0.21 (-0.35%)

06/10/16
RBCM
06/10/16
NO CHANGE
RBCM
Prothena data positive, says RBC Capital
RBc Capital believes that the Phase I data for Prothena's antibody program, '003, was positive. The firm thinks the treatment "could be a new psoriasis drug or go after other big inflammatory markets." The firm expects '003 to begin to get attention from investors, and it views the product as "somewhat de-risked." RBC keeps an Outperform rating on the shares.
08/03/16
LTCO
08/03/16
NO CHANGE
Target $80
LTCO
Buy
Prothena price target raised to $80 from $77 at Ladenburg
Ladenburg Thalmann analyst Robert Hazlett said the recently released clinical data from the Phase 1/2 study of NEOD001 continue to point to promising organ responses that do not appear to be related to prior plasma cell directed therapy. Noting there are catalysts upcoming for NEOD001, PRX002 and PRX003, the analyst raised his price target on the stock to $80, adding that he assigns a 70% probability of Prothena operating independently and a 30% probability to a takeover.
09/27/16
UBSW
09/27/16
NO CHANGE
Target $73
UBSW
Buy
Prothena management has continuity during CEO leave of absence, says UBS
UBS analyst Jeffrey Hung noted that Prothena's COO Gene Kinney will lead the company while its CEO, Dale Schenk, is on a medical leave of absence. Hung notes that the NEOD001 strategy is already largely in place and he believes the Board's confidence in Kinney, combined with his recent promotion, points to the potential for a natural succession. The analyst keeps a Buy rating and $73 price target on Prothena shares.
09/27/16
RBCM
09/27/16
NO CHANGE
RBCM
Prothena CEO change 'neutral, natural, and positive' says RBC Capital
Afte Prothena announced its CEO was taking a medical leave and that it was elevating its COO, Gene Kinney, to interim CEO, RBC Capital analyst Michael Yee says "this a a neutral and natural positive development." Yee reports that Kinney " has been generally in charge of and overseen the R&D and clinical development of their 3 lead programs and involved in leading discussions with the FDA." The analyst believes that the company had previously been planning for succession and that investors should not be surprised by this development, as they knew that the CEO had health problems. Yee keeps an Outperform rating on the shares.
VYGR Voyager Therapeutics
$11.94

-0.07 (-0.58%)

01/25/16
01/25/16
UPGRADE

On The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: American Express (AXP) upgraded to Perform from Underperform at Oppenheimer... BankMutual (BKMU) upgraded to Outperform from Market Perform at Hovde Group... Black Hills (BKH) upgraded on acquisition at BMO Capital... Bruker (BRKR) upgraded to Buy from Hold at Cantor... Cedar Fair (FUN) upgraded to Conviction Buy from Buy at Goldman... Charles Schwab (SCHW) upgraded to Buy from Neutral at Nomura... Corporate Office Properties (OFC) upgraded to Buy from Neutral at Mizuho... Entegris (ENTG) upgraded on valuation, outlook at Pacific Crest... First Financial upgraded to Outperform from Market Perform at Keefe Bruyette... Goldman Sachs (GS) upgraded to Buy from Neutral at Nomura... Graphic Packaging (GPK) upgraded to Outperform from Neutral at Macquarie... Home Depot (HD) upgraded to Buy from Hold at Deutsche Bank... Intel (INTC) upgraded to Outperform from Neutral at Macquarie... J.B. Hunt (JBHT) upgraded to Buy from Hold at BB&T... Magna (MGA) upgraded to Buy from Neutral at Citi... Masco (MAS) upgraded to Buy from Hold at Evercore ISI... Mattel (MAT) upgraded to Conviction Buy from Buy at Goldman... O'Reilly Automotive (ORLY) upgraded to Buy from Hold at Deutsche Bank... PACCAR (PCAR) upgraded to Buy from Neutral at Citi... People's United (PBCT) upgraded to Neutral from Underweight at Piper Jaffray... Quality Systems (QSII) upgraded to Overweight from Neutral at Piper Jaffray... RadiSys (RSYS) upgraded to Buy from Hold at Needham... Standard Motor (SMP) upgraded to Buy from Neutral at CL King... Swedbank (SWDBY) upgraded to Hold from Underperform at Jefferies... Toll Brothers (TOL) upgraded to Strong Buy from Outperform at Raymond James... Voyager Therapeutics (VYGR) upgraded to Neutral from Sell at Chardan... Yahoo (YHOO) upgraded to Buy from Hold at Pivotal Research.
05/20/16
WELS
05/20/16
INITIATION
WELS
Outperform
Voyager Therapeutics initiated with an Outperform at Wells Fargo
Target $35-$43.
06/22/16
PIPR
06/22/16
NO CHANGE
Target $37
PIPR
Overweight
Voyager interim data bodes well for clinical outcome, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said the interim Phase 1B results for VY-AADC01 in Parkinson's Disease build on the prior patients' data from this cohort and bode well for the full six-month data that is expected to be released by year end. The analyst, who notes that Voyager Therapeutics also has 6 preclinical programs beyond the Parkinson's gene therapy program, reiterates an Overweight rating and $37 price target on the stock.
07/14/16
STFL
07/14/16
INITIATION
Target $33
STFL
Buy
Voyager Therapeutics initiated with a Buy at Stifel
Target $33.

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

12:16
12/09/16
12/09
12:16
12/09/16
12:16
Technical Analysis
NYSE market internals summary »

Breadth is mixed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

12:16
12/09/16
12/09
12:16
12/09/16
12:16
Technical Analysis
NASDAQ market internals summary »

Volume is lighter for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITIC

Investors Title Company

$155.05

1.15 (0.75%)

12:15
12/09/16
12/09
12:15
12/09/16
12:15
Hot Stocks
Breaking Hot Stocks news story on Investors Title Company »

Investors Title Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$109.53

1.1 (1.01%)

12:14
12/09/16
12/09
12:14
12/09/16
12:14
Hot Stocks
USW affirms 1,300 Carrier jobs still going to Mexico, only 730 jobs staying »

The United Steelworkers,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

ITIC

Investors Title Company

$155.05

1.15 (0.75%)

12:10
12/09/16
12/09
12:10
12/09/16
12:10
Hot Stocks
Breaking Hot Stocks news story on Investors Title Company »

Investors Title Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVN

InvenSense

$10.44

2.17 (26.24%)

12:10
12/09/16
12/09
12:10
12/09/16
12:10
Options
Sweep call buyers in Invensense before a trading halt »

Sweep call buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

PBH

Prestige Brands

$47.19

0.66 (1.42%)

12:10
12/09/16
12/09
12:10
12/09/16
12:10
Hot Stocks
Breaking Hot Stocks news story on Prestige Brands »

Manor Road Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 09

    Jan

PPC

Pilgrim's Pride

$18.30

-0.08 (-0.44%)

, HRL

Hormel Foods

$34.24

0.15 (0.44%)

12:09
12/09/16
12/09
12:09
12/09/16
12:09
Hot Stocks
USDA raises red meat and poultry production forecast for 2016 »

In the World Agricultural…

PPC

Pilgrim's Pride

$18.30

-0.08 (-0.44%)

HRL

Hormel Foods

$34.24

0.15 (0.44%)

SAFM

Sanderson Farms

$85.38

-0.88 (-1.02%)

TSN

Tyson Foods

$60.99

-0.605 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 15

    Dec

ANDE

Andersons

$42.25

0.95 (2.30%)

, POT

Potash

$19.67

0.39 (2.02%)

12:07
12/09/16
12/09
12:07
12/09/16
12:07
Hot Stocks
USDA U.S. wheat, corn estimates unchanged in December report »

In the World Agricultural…

ANDE

Andersons

$42.25

0.95 (2.30%)

POT

Potash

$19.67

0.39 (2.02%)

MOS

Mosaic

$30.85

0.6741 (2.23%)

DD

DuPont

$74.85

0.165 (0.22%)

SYT

Syngenta

$80.25

0.2 (0.25%)

CMP

Compass Minerals

$80.41

-0.09 (-0.11%)

CF

CF Industries

$30.25

-0.12 (-0.40%)

AGU

Agrium

$108.81

2.16 (2.03%)

BG

Bunge

$73.41

0.01 (0.01%)

MON

Monsanto

$104.79

0.09 (0.09%)

ADM

Archer Daniels

$46.32

0.35 (0.76%)

IPI

Intrepid Potash

$2.68

0.29 (12.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 27

    Jan

MMYT

MakeMyTrip

$23.85

-0.7 (-2.85%)

12:06
12/09/16
12/09
12:06
12/09/16
12:06
Hot Stocks
Breaking Hot Stocks news story on MakeMyTrip »

Capital World Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEP

NextEra Energy Partners

$25.25

0.3645 (1.46%)

12:05
12/09/16
12/09
12:05
12/09/16
12:05
Hot Stocks
Breaking Hot Stocks news story on NextEra Energy Partners »

Neuberger Berman reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDX

Celldex

$3.74

-0.02 (-0.53%)

12:05
12/09/16
12/09
12:05
12/09/16
12:05
Hot Stocks
Breaking Hot Stocks news story on Celldex »

KLP Enterprises reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSX

Phillips 66

$87.35

-0.28 (-0.32%)

, CVX

Chevron

$115.51

0.3406 (0.30%)

12:04
12/09/16
12/09
12:04
12/09/16
12:04
Hot Stocks
Phillips 66 announces 2017 capital budget of $2.7B »

Phillips 66 (PSX)…

PSX

Phillips 66

$87.35

-0.28 (-0.32%)

CVX

Chevron

$115.51

0.3406 (0.30%)

DPM

DCP Midstream

$35.39

0.225 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CME

CME Group

$122.29

1.44 (1.19%)

12:02
12/09/16
12/09
12:02
12/09/16
12:02
Hot Stocks
CME Group appoints Julie Winkler as Chief Commercial Officer »

CME Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTPH

Tetraphase

$4.63

0.14 (3.12%)

12:01
12/09/16
12/09
12:01
12/09/16
12:01
Technical Analysis
Tetraphase moves higher on unconfirmed takeover chatter »

Shares were last up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARNC

Arconic

$21.57

0.66 (3.16%)

12:00
12/09/16
12/09
12:00
12/09/16
12:00
Options
Arconic attracts bullish flow »

Arconic attracts bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

NRE

Northstar Realty Europe Corp.

$12.19

0.42 (3.57%)

, NSAM

NorthStar Asset Management

$15.16

0.16 (1.07%)

11:59
12/09/16
12/09
11:59
12/09/16
11:59
Periodicals
Bow Street offers to buy Northstar Realty Europe for $13/share, Reuters reports »

Bow Street, a hedge fund…

NRE

Northstar Realty Europe Corp.

$12.19

0.42 (3.57%)

NSAM

NorthStar Asset Management

$15.16

0.16 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

TTPH

Tetraphase

$4.63

0.14 (3.12%)

11:57
12/09/16
12/09
11:57
12/09/16
11:57
Rumors
Rumor moving shares of Tetraphase »

Rumor: Tetraphase moves…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVN

InvenSense

$8.33

0.06 (0.73%)

11:55
12/09/16
12/09
11:55
12/09/16
11:55
Periodicals
Japan's TDK in talks to acquire InvenSense, Reuters reports »

Japan's TDK Corp is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

SHLD

Sears

$12.76

0.64 (5.28%)

11:55
12/09/16
12/09
11:55
12/09/16
11:55
Options
Sears put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVN

InvenSense

$8.34

0.07 (0.85%)

11:53
12/09/16
12/09
11:53
12/09/16
11:53
Hot Stocks
Breaking Hot Stocks news story on InvenSense »

Invensense trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

INSW

International Seaways

$14.21

0.67 (4.95%)

11:50
12/09/16
12/09
11:50
12/09/16
11:50
Hot Stocks
Breaking Hot Stocks news story on International Seaways »

BlueMountain Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVN

InvenSense

$8.34

0.065 (0.79%)

11:48
12/09/16
12/09
11:48
12/09/16
11:48
Periodicals
Breaking Periodicals news story on InvenSense »

InvenSense in acquistion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

INVN

InvenSense

$8.34

0.065 (0.79%)

11:48
12/09/16
12/09
11:48
12/09/16
11:48
Hot Stocks
Breaking Hot Stocks news story on InvenSense »

InvenSense halted for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

MDCO

The Medicines Co.

$32.82

-0.55 (-1.65%)

11:47
12/09/16
12/09
11:47
12/09/16
11:47
Hot Stocks
The Medicines Co. executive buys 105,500 shares of stock »

The Medicines Co. Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.